CryoCath Technologies Inc.
This article was originally published in Start Up
CryoCath Technologies is looking to develop a cryoablation platform with applications in several therapeutic areas, among them arrhythmias, post angioplasty restenosis, female sterilization and palliative cancer care.
You may also be interested in...
Despite widespread and increasing prevalence, atrial fibrillation has frustrated clinicians, device companies, and investors, resulting in only a small number of doctors treating a small number of patients. Ablation Frontiers believes its system will finally enable many more doctors to treat all types of AF patients because it is developing products and procedures that are simpler for doctors to use and perform, finally providing a broad-based solution to this rapidly growing market.
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.